EUCTR2012-000167-25-FR进行中（未招募）1 期
A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer.
ICANCER0 个研究点目标入组 75 人开始时间: 2012年8月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Metastatic colorectal cancer expressing the wtKRAS status
- •2.No previous EGFR targeted therapy.
- •3.Must have failed a prior regimen containing irinotecan for metastatic disease and a prior regimen containing oxaliplatin for metastatic disease
- •4.Must have previously received a thymidylate synthase inhibitor (eg, fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) at any point for treatment of colorectal cancer (CRC)
- •5.Life expectancy of at least 3 months.
- •6.Patient with ECOG = 1
- •7.Patients aged = 18.
- •8.Patient with measurable lesions according to RECIST criteria (version 1.1) with spiral CT scan and defined as = 10 mm in longest diameter and 2X the slice thickness for extra nodal lesions and/or > 15 mm in short axis diameter for nodal lesions
- •9.Patient able to receive adequate oral nutrition of = 1500 calories per day and free of significant nausea and vomiting
- •10.Patient with adequate organ function:
- •Absolute neutrophil count (ANC) = 1.5 x 109/L
- •Haemoglobin = 9 g/dL
- •Platelets (PTL) = 100 x 109/L
- •AST/ALT = 2.5 x ULN (= 5 x ULN in case of liver metastases)
- •GammaGT < 3 x ULN (< 5 x ULN in case of liver involvement)
- •Bilirubin = 1.5 x ULN
- •Creatinine clearance = 50 mL/min (Cockcroft and Gault formula)
- •11.Adequate contraception if applicable.
- •12.Ability to take oral medication in the opinion of the investigator.
- •13.Patient able and willing to comply with study procedures as per protocol
- •14.Patient able to understand and willing to sign and date the written voluntary informed consent form at screening visit prior to any protocol-specific procedures
- •15.Patient affiliated to a social security regimen
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous EGFR targeted therapy.
- •2.Mutant KRAS status
- •3.Prior severe reaction to a monoclonal antibody
- •4.Clinically relevant cardiovascular abnormalities, as judged by the investigator, such as, but not limited to, uncontrolled hypertension, congestive heart failure NYHA classification > III, unstable angina, myocardial infarction within six months prior to randomisation, or poorly controlled arrhythmia
- •5.Cardiac left ventricular dysfunction with resting ejection fraction of less than institutional lower limit of normal (if no lower limit of normal is defined in the institution, the lower limit is 50%)
- •6.Symptomatic brain metastases requiring treatment
- •7.Major surgery within 28 days or minor surgery within 14 days of the start of the study treatment
- •8.Radiotherapy less than two weeks prior to the start of the study treatment
- •9.Systemic chemotherapy, hormonal therapy, immunotherapy = 28 days before study treatment
- •10.No major comorbidity that may preclude the delivery of treatment or active infection (HIV or chronic hepatitis B or C) or uncontrolled diabetes.
- •11.Concomitant occurrence of another cancer, or history of cancer within the past five years except in situ carcinoma of the cervix treated or basal cell carcinoma or squamous cell carcinoma.
- •12.Known pre-existing interstitial lung disease
- •13.Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn’s disease, malabsorption, or CTCAE grade >2 diarrhea of any etiology
- •14.Pregnant woman or lactating woman.
- •15.Persons deprived of liberty or under guardianship.
- •16.Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
研究者
相似试验
进行中（未招募）
不适用
A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage IIIB/IV non-small cell lung cancerHistologically- or cytologically-confirmed diagnosis of non-predominantly squamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-002144-42-DKGlaxoSmithKline R&D Limited150
进行中（未招募）
不适用
A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage IIIB/IV non-small cell lung cancerHistologically- or cytologically-confirmed diagnosis of non-predominantly squamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-002144-42-DEGlaxoSmithKline R&D Limited150
进行中（未招募）
不适用
A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage IIIB/IV non-small cell lung cancerHistologically- or cytologically-confirmed diagnosis of non-predominantly squamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-002144-42-NLGlaxoSmithKline R&D Limited150
进行中（未招募）
不适用
A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage IIIB/IV non-small cell lung cancerHistologically- or cytologically-confirmed diagnosis of non-predominantly squamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-002144-42-BEGlaxoSmithKline R&D Limited150
进行中（未招募）
1 期
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyEUCTR2024-000203-67-Outside-EU/EEAKadmon Corporation, LLC